<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37257088</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2641-7650</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Kidney360</Title><ISOAbbreviation>Kidney360</ISOAbbreviation></Journal><ArticleTitle>Non-Full House Membranous Lupus Nephritis Represents a Clinically Distinct Subset.</ArticleTitle><Pagination><StartPage>935</StartPage><EndPage>942</EndPage><MedlinePgn>935-942</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.34067/KID.0000000000000161</ELocationID><Abstract><AbstractText Label="KEY POINTS">Non-full house (NFH) membranous lupus nephritis (MLN) is a minor subset of all MLN cases. Patients with NFH MLN tend to be older when diagnosed with systemic lupus erythematosus, undergo first renal biopsy at an older age, and have fewer extrarenal systemic manifestations. Lower load of C3 glomerular deposits seen in NFH MLN biopsies suggests attenuation of complement-mediated injury, which may have wider systemic implications.</AbstractText><AbstractText Label="BACKGROUND">Renal involvement in systemic lupus erythematosus (SLE) is a key predictor of morbidity and mortality. Immunofluorescence (IF) staining of glomeruli is typically positive for IgG, IgA, IgM, C3, and C1q&#x2014;the full house (FH) pattern. However, a subset of patients with membranous lupus nephritis (MLN) have a Non-FH (NFH) IF pattern more typical of idiopathic membranous nephropathy.</AbstractText><AbstractText Label="METHODS">From a multi-institutional cohort of 113 MLN cases, we identified 29 NFH MLN biopsies. NFH MLN was defined by IF criteria: &#x2265;1+ glomerular capillary loop IgG staining and&lt;1+ IgA, IgM, and C1q. FH MLN was defined as &#x2265;1+ staining for all five antibodies. Intermediate (Int) cases did not meet criteria for FH or NFH. We compared the pathological and clinical characteristics and outcomes among patients with FH, NFH, and Int IF patterns on kidney biopsy.</AbstractText><AbstractText Label="RESULTS">NFH MLN represents a subset of MLN biopsies (13.4%). Compared with patients with FH MLN, patients with NFH MLN were older at SLE diagnosis (29 versus 22.5 years), had a longer time to initial kidney biopsy (8 versus 3.16 years), and had fewer SLE manifestations (2.5 versus 3.36 involved systems). NFH MLN biopsies showed lower C3 IF intensity (1.16+ versus 2.38+). Int biopsies had findings intermediate between those of NFH and FH groups.</AbstractText><AbstractText Label="CONCLUSIONS">NFH IF pattern defines a small subset of MLN biopsies and appears to be associated with milder clinical manifestations and slower disease progression. Less robust C3 deposition in NFH MLN may suggest a pathophysiology distinct from that of FH MLN.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Julia</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-8970-9777</Identifier><AffiliationInfo><Affiliation>Department of Pathology, University of California, San Francisco, San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Croom</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-4936-0571</Identifier><AffiliationInfo><Affiliation>Department of Pathology, University of California, San Francisco, San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troxell</LastName><ForeName>Megan L</ForeName><Initials>ML</Initials><Identifier Source="ORCID">0000-0002-1590-2803</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Stanford University, Palo Alto, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kambham</LastName><ForeName>Neeraja</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pathology, Stanford University, Palo Alto, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zuckerman</LastName><ForeName>Jonathan E</ForeName><Initials>JE</Initials><Identifier Source="ORCID">0000-0001-9758-2147</Identifier><AffiliationInfo><Affiliation>Department of Pathology, University of California, Los Angeles, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andeen</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-4882-6640</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Oregon Health and Science University, Portland, Oregon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dall'Era</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine, University of California, San Francisco, San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Raymond</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-7883-8984</Identifier><AffiliationInfo><Affiliation>Division of Nephrology, Department of Medicine, University of California, San Francisco, San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walavalkar</LastName><ForeName>Vighnesh</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of California, San Francisco, San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laszik</LastName><ForeName>Zoltan G</ForeName><Initials>ZG</Initials><Identifier Source="ORCID">0000-0003-0511-8764</Identifier><AffiliationInfo><Affiliation>Department of Pathology, University of California, San Francisco, San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Urisman</LastName><ForeName>Anatoly</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8364-5303</Identifier><AffiliationInfo><Affiliation>Department of Pathology, University of California, San Francisco, San Francisco, California.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Kidney360</MedlineTA><NlmUniqueID>101766381</NlmUniqueID><ISSNLinking>2641-7650</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Kidney360. 2023 Jul 1;4(7):868-869</RefSource><PMID Version="1">37499070</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015433" MajorTopicYN="Y">Glomerulonephritis, Membranous</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>M. Dall'Era reports the following&#x2014;consultancy: AstraZeneca, Aurinia, BMS, GSK, Janssen, and Pfizer and research funding: Horizon. R. Hsu reports the following&#x2014;research funding: Travere Therapeutics. M.L. Troxell reports the following&#x2014;employer: Stanford University; and other interests or relationships: International Society for Immunohistochemistry and Molecular Morphology (Board) isimm.org. A. Urisman reports the following&#x2014;consultancy: Pliant Therapeutics. J.E. Zuckerman reports the following&#x2014;consultancy: Leica Biosystems and PAthai; honoraria: ApotheCom; and advisory or leadership role: Pathologyoutlines.com. All remaining authors have nothing to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>31</Day><Hour>19</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>31</Day><Hour>15</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37257088</ArticleId><ArticleId IdType="pmc">PMC10371271</ArticleId><ArticleId IdType="doi">10.34067/KID.0000000000000161</ArticleId><ArticleId IdType="pii">02200512-202307000-00010</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358(9):929&#x2013;939. doi:10.1056/NEJMra071297</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra071297</ArticleId><ArticleId IdType="pubmed">18305268</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110&#x2013;2121. doi:10.1056/NEJMra1100359</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1100359</ArticleId><ArticleId IdType="pubmed">22129255</ArticleId></ArticleIdList></Reference><Reference><Citation>Bultink IEM, DeVries F, van Vollenhoven RF, Lalmohamed A. Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls. Rheumatology (Oxford). 2021;60(1):207&#x2013;216. doi:10.1093/rheumatology/keaa267</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa267</ArticleId><ArticleId IdType="pmc">PMC8312724</ArticleId><ArticleId IdType="pubmed">32653901</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter EE, Barr SG, Clarke AE. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol. 2016;12(10):605&#x2013;620. doi:10.1038/nrrheum.2016.137</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2016.137</ArticleId><ArticleId IdType="pubmed">27558659</ArticleId></ArticleIdList></Reference><Reference><Citation>Weening JJ D&#x2019;Agati VD Schwartz MM, et al. . The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65(2):521&#x2013;530. doi:10.1111/j.1523-1755.2004.00443.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1523-1755.2004.00443.x</ArticleId><ArticleId IdType="pubmed">14717922</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsokos GC, Lo MS, Reis PC, Sullivan KE. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2016;12(12):716&#x2013;730. doi:10.1038/nrrheum.2016.186</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2016.186</ArticleId><ArticleId IdType="pubmed">27872476</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson A. What&#x2019;s damaging the kidney in lupus nephritis? Nat Rev Rheumatol. 2016;12(3):143&#x2013;153. doi:10.1038/nrrheum.2015.159</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2015.159</ArticleId><ArticleId IdType="pmc">PMC4820834</ArticleId><ArticleId IdType="pubmed">26581344</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward F, Bargman JM. Membranous lupus nephritis: the same but different. Am J Kidney Dis. 2016;68(6):954&#x2013;966. doi:10.1053/j.ajkd.2016.07.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2016.07.026</ArticleId><ArticleId IdType="pubmed">27663040</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Vives E Sole C Moline T, et al. . Antibodies to M-type phospholipase A2 receptor (PLA2R) in membranous lupus nephritis. Lupus. 2019;28(3):396&#x2013;405. doi:10.1177/0961203319828521</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319828521</ArticleId><ArticleId IdType="pubmed">30760090</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasparotto M, Gatto M, Binda V, Doria A, Moroni G. Lupus nephritis: clinical presentations and outcomes in the 21st century. Rheumatology (Oxford). 2020;59(suppl 5):v39&#x2013;v51. doi:10.1093/rheumatology/keaa381</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa381</ArticleId><ArticleId IdType="pmc">PMC7751166</ArticleId><ArticleId IdType="pubmed">33280015</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh SV, Almaani S, Brodsky S, Rovin BH. Update on lupus nephritis: core curriculum 2020. Am J Kidney Dis. 2020;76(2):265&#x2013;281. doi:10.1053/j.ajkd.2019.10.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2019.10.017</ArticleId><ArticleId IdType="pubmed">32220510</ArticleId></ArticleIdList></Reference><Reference><Citation>Parodis I, Tamirou F, Houssiau FA. Prediction of prognosis and renal outcome in lupus nephritis. Lupus Sci Med. 2020;7(1):e000389. doi:10.1136/lupus-2020-000389</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2020-000389</ArticleId><ArticleId IdType="pmc">PMC7046967</ArticleId><ArticleId IdType="pubmed">32153796</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanly JG O&#x2019;Keeffe AG Su L, et al. . The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford). 2016;55(2):252&#x2013;262. doi:10.1093/rheumatology/kev311</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kev311</ArticleId><ArticleId IdType="pmc">PMC4939728</ArticleId><ArticleId IdType="pubmed">26342222</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoover PJ, Costenbader KH. Insights into the epidemiology and management of lupus nephritis from the US rheumatologist&#x2019;s perspective. Kidney Int. 2016;90(3):487&#x2013;492. doi:10.1016/j.kint.2016.03.042</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2016.03.042</ArticleId><ArticleId IdType="pmc">PMC5679458</ArticleId><ArticleId IdType="pubmed">27344205</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu F, Haas M, Glassock R, Zhao MH. Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nat Rev Nephrol. 2017;13(8):483&#x2013;495. doi:10.1038/nrneph.2017.85</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneph.2017.85</ArticleId><ArticleId IdType="pubmed">28669995</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajema IM Wilhelmus S Alpers CE, et al. . Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified national institutes of health activity and chronicity indices. Kidney Int. 2018;93(4):789&#x2013;796. doi:10.1016/j.kint.2017.11.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2017.11.023</ArticleId><ArticleId IdType="pubmed">29459092</ArticleId></ArticleIdList></Reference><Reference><Citation>Jennette JC, Iskandar SS, Dalldorf FG, Jennette JC. Pathologic differentiation between lupus and nonlupus membranous glomerulopathy. Kidney Int. 1983;24(3):377&#x2013;385. doi:10.1038/ki.1983.170</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.1983.170</ArticleId><ArticleId IdType="pubmed">6358633</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin HA, III, Muenz LR, Joyce KM, Antonovych TT, Balow JE. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int. 1984;25(4):689&#x2013;695. doi:10.1038/ki.1984.75</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.1984.75</ArticleId><ArticleId IdType="pubmed">6482173</ArticleId></ArticleIdList></Reference><Reference><Citation>Loupy A Haas M Solez K, et al. . The Banff 2015 Kidney Meeting Report: current challenges in rejection classification and prospects for adopting molecular pathology. Am J Transplant. 2017;17(1):28&#x2013;41. doi:10.1111/ajt.14107</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.14107</ArticleId><ArticleId IdType="pmc">PMC5363228</ArticleId><ArticleId IdType="pubmed">27862883</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M Costenbader K Daikh D, et al. . 2019 European League against rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019;71(9):1400&#x2013;1412. doi:10.1002/art.40930</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40930</ArticleId><ArticleId IdType="pmc">PMC6827566</ArticleId><ArticleId IdType="pubmed">31385462</ArticleId></ArticleIdList></Reference><Reference><Citation>Greloni G Scolnik M Marin J, et al. . Value of repeat biopsy in lupus nephritis flares. Lupus Sci Med. 2014;1(1):e000004. doi:10.1136/lupus-2013-000004</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2013-000004</ArticleId><ArticleId IdType="pmc">PMC4225737</ArticleId><ArticleId IdType="pubmed">25396056</ArticleId></ArticleIdList></Reference><Reference><Citation>Marinaki S Kapsia E Liapis G, et al. . Clinical impact of repeat renal biopsies in patients with lupus nephritis: renal biopsy is essential especially later in the course of the disease. Eur J Rheumatol. 2020;7(1):2&#x2013;8. doi:10.5152/eurjrheum.2019.18146</Citation><ArticleIdList><ArticleId IdType="doi">10.5152/eurjrheum.2019.18146</ArticleId><ArticleId IdType="pmc">PMC7001996</ArticleId><ArticleId IdType="pubmed">31782721</ArticleId></ArticleIdList></Reference><Reference><Citation>Gururani S, Devarasetti PK, Uppin M, Rajasekhar L. Treatment outcomes in refractory lupus nephritis: data from an observational study. Lupus. 2021;30(11):1725&#x2013;1731. doi:10.1177/09612033211033980</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033211033980</ArticleId><ArticleId IdType="pubmed">34304627</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen CP, Messias NC, Silva FG, Messias E, Walker PD. Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies. Mod Pathol. 2013;26(5):709&#x2013;715. doi:10.1038/modpathol.2012.207</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/modpathol.2012.207</ArticleId><ArticleId IdType="pubmed">23196797</ArticleId></ArticleIdList></Reference><Reference><Citation>Lwezaula BF Ameh OI Ekrikpo UE, et al. . Diagnostic performance of glomerular PLA2R and THSD7A antibodies in biopsy confirmed primary membranous nephropathy in South Africans. BMC Nephrol. 2021;22(1):15. doi:10.1186/s12882-020-02216-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12882-020-02216-7</ArticleId><ArticleId IdType="pmc">PMC7791976</ArticleId><ArticleId IdType="pubmed">33413188</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrenreich T Porush JG Churg J, et al. . Treatment of idiopathic membranous nephropathy. N Engl J Med. 1976;295(14):741&#x2013;746. doi:10.1056/NEJM197609302951401</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM197609302951401</ArticleId><ArticleId IdType="pubmed">958260</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck LH Jr Bonegio RGB Lambeau G, et al. . M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11&#x2013;21. doi:10.1056/NEJMoa0810457</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0810457</ArticleId><ArticleId IdType="pmc">PMC2762083</ArticleId><ArticleId IdType="pubmed">19571279</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomas NM Beck LH Jr Meyer-Schwesinger C, et al. . Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2014;371(24):2277&#x2013;2287. doi:10.1056/NEJMoa1409354</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1409354</ArticleId><ArticleId IdType="pmc">PMC4278759</ArticleId><ArticleId IdType="pubmed">25394321</ArticleId></ArticleIdList></Reference><Reference><Citation>Sethi S Madden BJ Debiec H, et al. . Exostosin 1/Exostosin 2-associated membranous nephropathy. J Am Soc Nephrol. 2019;30(6):1123&#x2013;1136. doi:10.1681/ASN.2018080852</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2018080852</ArticleId><ArticleId IdType="pmc">PMC6551791</ArticleId><ArticleId IdType="pubmed">31061139</ArticleId></ArticleIdList></Reference><Reference><Citation>Caza TN Hassen SI Dvanajscak Z, et al. . NELL1 is a target antigen in malignancy-associated membranous nephropathy. Kidney Int. 2021;99(4):967&#x2013;976. doi:10.1016/j.kint.2020.07.039</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2020.07.039</ArticleId><ArticleId IdType="pmc">PMC7895854</ArticleId><ArticleId IdType="pubmed">32828756</ArticleId></ArticleIdList></Reference><Reference><Citation>Sethi S Debiec H Madden B, et al. . Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients. Kidney Int. 2020;98(5):1253&#x2013;1264. doi:10.1016/j.kint.2020.05.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2020.05.030</ArticleId><ArticleId IdType="pubmed">32534052</ArticleId></ArticleIdList></Reference><Reference><Citation>Truedsson L, Bengtsson AA, Sturfelt G. Complement deficiencies and systemic lupus erythematosus. Autoimmunity. 2007;40(8):560&#x2013;566. doi:10.1080/08916930701510673</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08916930701510673</ArticleId><ArticleId IdType="pubmed">18075790</ArticleId></ArticleIdList></Reference><Reference><Citation>Birmingham DJ, Hebert LA. The complement system in lupus nephritis. Semin Nephrol. 2015;35(5):444&#x2013;454. doi:10.1016/j.semnephrol.2015.08.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semnephrol.2015.08.006</ArticleId><ArticleId IdType="pubmed">26573547</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert L, Cosio F, Birmingham D. Complement and complement regulatory proteins. In: Neilson E, Couser W, editors. Immunologic Renal Diseases, 2nd ed. Lippincott Williams &amp; Williams; 2001:367&#x2013;393</Citation></Reference><Reference><Citation>Coppo R Peruzzi L Amore A, et al. . Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. Pediatr Nephrol. 2015;30(1):167&#x2013;172. doi:10.1007/s00467-014-2944-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00467-014-2944-y</ArticleId><ArticleId IdType="pubmed">25173358</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Husseini A, Hannan S, Awad A, Jennings S, Cornea V, Sawaya BP. Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab. Am J Kidney Dis. 2015;65(1):127&#x2013;130. doi:10.1053/j.ajkd.2014.07.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2014.07.031</ArticleId><ArticleId IdType="pubmed">25446020</ArticleId></ArticleIdList></Reference><Reference><Citation>Erkan D Aguiar CL Andrade D, et al. . 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014;13(6):685&#x2013;696. doi:10.1016/j.autrev.2014.01.053</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2014.01.053</ArticleId><ArticleId IdType="pubmed">24468415</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>